Welcome to our dedicated page for Dbv Technologies S A news (Ticker: DBVT), a resource for investors and traders seeking the latest updates and insights on Dbv Technologies S A stock.
The DBV Technologies S.A. (DBVT) news page on Stock Titan aggregates company announcements, regulatory disclosures, and clinical development updates for this clinical-stage biopharmaceutical issuer. DBV Technologies focuses on food allergies and other immunologic conditions with significant unmet medical need, using its proprietary Viaskin patch technology and epicutaneous immunotherapy (EPIT) platform.
Investors and followers of DBV Technologies can use this news feed to review company-issued press releases and market announcements. Recent communications from DBV Technologies have covered topics such as progress in its Viaskin Peanut clinical program in peanut-allergic toddlers and children, including the Phase 3 VITESSE trial in children aged 4 to 7 years. The company has reported that VITESSE met its primary endpoint and that safety results were consistent with the existing Viaskin Peanut clinical program, positioning this trial as a key milestone in its development strategy.
In addition to clinical data updates, DBV Technologies news items include information on supplemental safety studies in toddlers, participation in healthcare and investor conferences, and changes in leadership and board composition. The company also releases regulated information related to its Euronext Paris listing, such as monthly disclosures of total shares and voting rights and reports on its liquidity contract.
Regulatory filings summarized in press releases, including U.S. SEC Form 8-K reports, provide insight into financial results, equity financing arrangements, and other corporate events. By following DBV Technologies news, readers can track developments in the Viaskin platform, food allergy programs, and the company’s dual listing on Euronext Paris and the Nasdaq Capital Market.
DBV Technologies (DBVT) provided updates on its Viaskin Peanut program and reported Q2 2024 financial results. Key highlights:
- VITESSE Phase 3 study enrollment for 4-7 year olds with peanut allergy is on track to complete by Q3 2024
- Submitted labeling proposal to FDA for COMFORT Toddlers study in 1-3 year olds
- Q2 2024 cash balance of $66.2 million, with runway extended into Q1 2025 due to cost-saving measures
- Q2 2024 net loss of $60.5 million or $0.63 per share
- Operating expenses increased to $65.0 million in H1 2024 vs $50.7 million in H1 2023, driven by R&D costs
The company faces substantial doubt about its ability to continue as a going concern beyond Q1 2025 without additional capital.
DBV Technologies (Nasdaq: DBVT), a clinical-stage biopharmaceutical company, has announced it will host a conference call and live audio webcast on Tuesday, July 30th, at 5:30 p.m. ET to discuss its second quarter 2024 financial results and provide a business update. Interested participants can join the call via teleconference or access the live webcast on the company's website. The event details are as follows:
- Teleconference numbers:
United States: +1-877-346-6112
International: +1-848-280-6350
- Webcast: Available on the Investors & Media section of DBV's website
A replay of the presentation will be accessible on the company's website after the event.
DBV Technologies, a clinical-stage biopharmaceutical company listed on Euronext and Nasdaq under the ticker DBVT, released its half-year report on the liquidity contract with ODDO BHF. As of June 30, 2024, the liquidity account held 303,744 DBV Technologies shares and €62,415.60. This is an increase from the initial assets on July 1, 2018, which included 41,159 shares and €432,367.25. Between January 1, 2024, and June 30, 2024, 912 buy transactions and 694 sales transactions were conducted. The total volumes traded were 299,986 shares and €397,966 for purchases, and 219,230 shares and €310,114 for sales.
DBV Technologies, a clinical-stage biopharmaceutical company, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference. CEO Daniel Tassé will engage in a fireside chat on June 10, 2024, at 8:00 am EDT, and attend one-on-one investor meetings. The company focuses on treating food allergies and other immunologic conditions with significant unmet needs. A live webcast and a 90-day replay of the presentation will be available on DBV Technologies’ Investor Relations website.
As of May 31, 2024, the company reported a total of 96,493,078 shares outstanding. The total number of voting rights is 96,493,078, with a net voting right count of 96,236,383. These figures are in accordance with Article 223-16 of the General Regulations of the Autorité des Marchés Financiers.
DBV Technologies announced a change in the ADS ratio from one ADS for one-half of an ordinary share to one ADS for one ordinary share, effective June 7, 2024. This change will act as a one-for-two reverse ADS split, aiming to regain compliance with Nasdaq's minimum bid price requirement. Registered ADS holders must surrender their certificated ADSs for cancellation and will receive new ADSs in exchange. Uncertificated ADSs will be automatically exchanged. No fractional new ADSs will be issued; instead, they will be aggregated and sold, with proceeds distributed to ADS holders. This change will not affect DBV's underlying ordinary shares.
DBV Technologies, a clinical-stage biopharmaceutical company, announced its participation in the European Academy of Allergy and Clinical Immunology (EAACI) Congress from May 31 to June 3, 2024, in Valencia, Spain. The company will present data on accidental peanut consumption from its EPITOPE Phase 3 study and its ongoing open-label extension study in peanut-allergic toddlers aged 1 to 3 years.
The presentation by Dr. Nicolette Arends will describe the data collection. DBV will also host a symposium moderated by Dr. Stefania Arasi and Dr. Philippe Eigenmann, featuring lectures on the potential clinical applications of epicutaneous immunotherapy. Additionally, DBV will have an exhibit booth to showcase their ongoing clinical trials in peanut-allergic children.
CEO Daniel Tassé emphasized the importance of long-term safety and clinical data, while Chief Medical Officer Pharis Mohideen highlighted the real-world benefits of Viaskin Peanut in reducing allergic reactions over time.
DBV Technologies, a clinical-stage biopharmaceutical company, announced plans to change its American Depositary Shares (ADS) ratio from one ADS to half an ordinary share, to one ADS to one ordinary share. This change, effective June 3, 2024, will act like a one-for-two reverse ADS split, helping the company meet the Nasdaq minimum bid price requirement. Registered ADS holders must surrender their ADSs for cancellation, receiving one new ADS for every two surrendered. Uncertificated ADS holders will see an automatic exchange. The ticker symbol 'DBVT' remains unchanged, and no new ordinary shares will be issued or canceled.
DBV Technologies, a clinical-stage biopharmaceutical company, announced that all resolutions proposed at its 2024 Combined General Meeting were approved by shareholders. The meeting, chaired by Michel de Rosen, took place on May 16, 2024, in Châtillon, France. The resolutions cover various strategic and operational plans aimed at advancing DBV's focus on treatments for food allergies and immunologic conditions with significant unmet needs. Detailed results are available on the company's website.
DBV Technologies, a biopharmaceutical company, will participate in two investor conferences in May 2024. The CEO will present at the Citizens JMP Life Sciences Conference on May 13 and the H.C. Wainwright BioConnect Conference on May 20. The presentations will be available via live webcast on the company's website.
FAQ
What is the current stock price of Dbv Technologies S A (DBVT)?
What is the market cap of Dbv Technologies S A (DBVT)?
